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Objective To characterize the phenotypes of Dent disease in Chinese children and their heterozygous mothers
and to establish genetic diagnoses.
Study design Using a modified protocol, we screened 1288 individuals with proteinuria. A diagnosis of Dent dis-
ease was established in 19 boys from 16 families by the presence of loss of function/deleterious mutations in
CLCN5 or OCRL1. We also analyzed 16 available patients’ mothers and examined their pregnancy records.
ResultsWedetected 14 loss of function/deleteriousmutations ofCLCN5 in 15 boys and 2mutations ofOCRL1 in 4
boys. Of the patients, 16 of 19 had been wrongly diagnosed with other diseases and 11 of 19 had incorrect or un-
necessary treatment. None of the patients, but 6 of 14 mothers, had nephrocalcinosis or nephrolithiasis at diag-
nosis. Of the patients, 8 of 14 with Dent disease 1 were large for gestational age (>90th percentile); 8 of 15
(53.3%) had rickets. We also present predicted structural changes for 4 mutant proteins.
Conclusions Pediatric Dent disease often is misdiagnosed; genetic testing achieves a correct diagnosis. Neph-
rocalcinosis or nephrolithiasis may not be sensitive diagnostic criteria. We identified 10 novel mutations in CLCN5
andOCRL1. The possibility that alteredCLCN5 function could affect fetal growth and a possible link between a high
rate of rickets and low calcium intake are discussed. (J Pediatr 2016;174:204-10).
D
ent disease (MIM 300009, 300555) is a rare X-linked recessive disorder. Progressive proximal renal tubulopathy
is considered to be fundamental, with impaired tubular reabsorption of proteins that pass through the glomerular
filtration barrier.1,2 Two distinct X-linked genes, chloride voltage-gated channel 5 (CLCN5, Entrez Gene ID: 1184)
and oculocerebrorenal syndrome of Lowe (OCRL1, Entrez Gene ID: 4952), underlie the disease.3,4 Based on the responsible
genes, Dent disease is divided into Dent disease 1 (MIM 300009) for CLCN5-related disease and Dent disease 2 (MIM
300555) for OCRL1-related disease. CLCN5 is responsible for 50%-60% of Dent disease1 and encodes the H(+)/Cl()
exchange transporter 5/chloride channel protein 5 (CLC-5, Uniprot ID: P51795). OCRL1 is responsible for 15% of DentFrom the 1Department of Medical Genetics, Genome
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larities with it, are located in the 30 part of the gene.5 Both genes play important
roles in the endocytosis-based reabsorption and processing of low-molecular-
weight proteins from the renal tubular brush border.1,2,6-11 The responsible
gene(s) for the remaining 25%-35% of patients with Dent disease have not
yet been identified.1
The most common clinical manifestations of Dent disease are low-molecular-
weight proteinuria, hypercalcuria, nephrocalcinosis, nephrolithiasis, and pro-
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24hUCa 24-hour urine calcium
b2MG b2-microglobulin
Ca/Cr Calcium/creatinine
CBS Cystathionine betasynthase
CLC-5 H(+)/Cl() exchange transporter 5/chloride channel protein 5
LGA Large for gestational age
OCRL1 Inositol polyphosphate 5-phosphatase OCRL-1/Lowe (oculocerebrorenal) syndrome
protein
SGA Small for gestational age
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Volume 174  July 2016different ethnicities has been reported.12-15 Data from het-
erozygous mothers and data concerning intrauterine growth
of patients have been lacking in the vast majority of patients
described previously. Two patients with Dent disease 1 were
large for gestational age (LGA).16
Methods
We screened 1288 individuals with proteinuria, who were
referred to us, the major referral center for childhood kidney
diseases in Guangdong Province, China, from January 2009
until December 2013, using a protocol modified from that
recommended by Edvardsson et al.17 There was no specific
clinical feature except growth abnormalities, such as short
stature and/or lower body weight (see Results). Eight patients
had polyuria compared with standards for different-aged
Chinese children.18 For patients in whom genetic testing
confirmed the diagnosis, we examined retrospectively all
available medical records. These records were evaluated ac-
cording to the criteria for newborns recommended by the
Group of Neonatology, Pediatric Society, Chinese Medical
Association.19 Patients’ mothers also were studied where
available, including any records from pregnancy.
Fifty individuals who were judged completely healthy by
our medical examinations were collected as controls and
were studied in the same manner. The study was approved
by the ethics committee of Sun Yat-sen University. Informed
consent was obtained from all participants, their parents, or
guardians. Principles outlined in the Declaration of Helsinki
were followed.
Laboratory investigations included routine urine testing,
the first-line urinary test in Chinese hospitals. This testing in-
cludes semiqualitative urinary protein. The routine urinary
test also includes urinary gravity, pH, leukocyte esterase, ni-
trite, glucose, urine occult blood, ketone bodies, urobilino-
gen, and urine sediments examination on AUTION MAX
UF1000i-AX4280 (Sysmex, Kobe, Japan) and Sysmex UF-
1000i (Sysmex). Laboratory investigations also included
blood and urinary chemistry. Low-molecular-weight pro-
teinuria was determined by increased urinary b2-microglo-
bulin (b2MG), analyzed on a BN ProSpec automated
analyzer (Siemens, Munich, Germany); hematuria, glucosu-
ria, and aminoaciduria were measured with Sysmex UF-
1000i (Sysmex); 24-hour urine calcium (24hUCa) and
urinary calcium/creatinine (Ca/Cr) were determined by Vi-
tros Fusion 5.1 (Sysmex). Serum electrolytes, sodium, potas-
sium, calcium, chloride, cholesterol, phosphate, magnesium,
blood urinary nitrogen, serum creatinine, and alkaline phos-
phatase were measured on an ARCHITECT C16000 (Abbott,
Abbott Park, Illinois); 25-OH-vitamin D3 was determined by
HITACHI cobas 6000 (Roche, Rotkreuz, Switzerland), para-
thyroid hormone on the ARCHITECT C16000 (Abbott) and
ARCHITECT i4000 (Abbott).
Renal Pathology
Renal biopsy had been performed in 14 of 19 patients. The
slides were examined by light and electron microscopy.Immunohistochemistry with antibodies against IgA, IgG,
IgM, complement 3, complement 1q, and fibrinogen were
performed according to the manufacturer’s instructions
(Dako A/S, Glostrup, Denmark).
Renal Ultrasound Examination
All patients and their available mothers underwent renal ul-
trasound examinations. Nephrocalcinosis was diagnosed
when there was visible calcification.20 Nephrolithiasis was
considered when the ultrasound examination showed an
echogenic focus (preferably with clear acoustic shadowing)
in renal pelvis or calyx or hydronephrosis.21
Skeletal Radiographs and Rickets
Of 16 patients who had radiograph examinations for possible
bone abnormalities, rickets was diagnosed in 8 patients on
the basis of bone deformity on physical examination and
the presence of radiographic abnormalities in the wrists
(metaphyseal fraying and cupping of the distal radius and
ulna), with the support of laboratory testing (elevated serum
alkaline phosphatase activity, or hypocalcemia, or hypophos-
phatemia).22,23 Osteomalacia was diagnosed when patients
had bone pain and tenderness, muscle weakness, and/or signs
of tetany in combination with decreased bone mineral den-
sity (measured in the forearm, lumbar spine, and hip), sup-
ported by laboratory test results as for rickets.22,24
Mutation Detection by Sanger Sequencing
Genomic DNA was extracted from peripheral blood of the 23
patients with clinically diagnosed or suspected Dent disease,
10 available mothers, and 50 control individuals via QIAamp
Blood DNA Kits (QIAGEN, Hilden, Germany). Polymerase
chain reaction was performed to amplify all exons and
exon–intron boundaries of CLCN5 and OCRL1 with specific
primers designed with Oligo6.0 (http://www.oligo.net/
downloads.html). Polymerase chain reaction products were
sequenced on an ABI 3730XL Automated DNA Sequencer
with a BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, California). The results
were compared with GenBank sequences NM_000084.4 for
CLCN5 and NM_000276.3 for OCRL1 retrieved from the
UCSC database (http://genome.ucsc.edu/). Mutation
nomenclature recommended by den Dunnen and Antonara-
kis (http://www.hgvs.org/mutnomen/)25 was adopted.
Bioinformatics Analyses
For each of the identified variations we searched the Human
Gene Mutation Database (http://www.hgmd.org/), the 1000
Genome Project (http://www.1000genomes.org/), the dbSNP
(http://www.ncbi.nlm.nih.gov/snp), and the Exome Variant
Server (http://evs.gs.washington.edu/EVS/) to determine
whether the mutation had been reported. To determine
possible biological implications of the variations, we per-
formed cross-species alignment with 5 orthologues (Nomas-
cus, Canine, Mouse, Gallus, and Xenopus) by CLUSTAL X
(1.81).26 We used SIFT (http://sift.jcvi.org/) and PolyPhen2
(http://genetics.bwh.harvard.edu/pph2/) to predict possible205
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used the National Center for Biotechnology Information
Open Reading Frame Finder (http://www.ncbi.nlm.nih.gov/
gorf/gorf.html) to predict consequences of the mutations.
Domain information for proteins was obtained with Pfam
(http://pfam.xfam.org/).
Structural Modeling of CLC-5 and Structure
Alignment of OCRL1
Structural modeling of human CLC-5 was performed with
the MODELLER module in Discovery Studio 3.0 (Accelrys,
San Diego, California) based on the recently reported struc-
ture of a eukaryotic chloride channel transporter from Cya-
nidioschyzon merolae (PDB ID: 3ORG).27 Four extracellular
loop regions were deleted because of the lack of sequence ho-
mology or missing electron density in the template structure.
The refined model was validated by the VERIFY-3D program
in Discovery Studio 3.0.
Structural alignment of OCRL1 with homologous pro-
teins: Type II inositol 1,4,5-trisphosphate 5-phosphatase
(PDB ID: 4CML) and SH2 domain-containing inositol 50-
phosphatase 2 (PDB ID: 3NR8) were performed using
PyMOL.28Results
Clinical Diagnosis and Unnecessary Treatment
before Reaching the Correct Diagnosis
Of 23 patients provisionally diagnosed with Dent disease on
clinical grounds, the diagnosis was confirmed in 19 patients
by genetic testing (Table I).29 The presenting symptom in all
of the 19 confirmed patients was urinary abnormalities
(Table II); their blood biochemistry results are shown in
Table III.30,31 Thirteen patients were previously diagnosedTable I. Previous diagnoses and mutations of patients with D
Previous diagnosis at local hospital
Dent disease 1
P1 Nephrosis c.15
P2 Nephrosis c.83
P3 ? c.74
P4 Bartter syndrome c.78
P5 Nephrotic syndrome and then Bartter syndrome c.79
P6 Bartter syndrome c.21
P7 Nephrotic syndrome c.82
P8 ? c.81
P9 Nephrotic syndrome c.81
P10 Nephrosis c.24
P11 Nephrotic syndrome c.16
P12 Nephrotic syndrome c.72
P13* Nephrosis ChrX
P14 Nephrosis c.11
P15 Nephrosis c.17
Dent disease 2
P16 Nephrotic syndrome c.83
P17 ? c.83
P18 Bartter syndrome c.52
P19 Nephrosis c.52
P8 and P9 from family 8; P16 and P17 from family 15; P18 and P19 from family 16; the other pati
*This patient has been reported in Human Genetics.29
206with nephrotic syndrome or nephrosis (Table I). Four
patients were diagnosed with Bartter syndrome, including
P5 from family 5 who were first diagnosed with nephrotic
syndrome and then Bartter syndrome (Table I). Eleven
of the 19 patients had been treated with prednisolone,
methylprednisolone, cyclosporine, cyclophosphamide, or
alternative medicine. None of the patients with Dent
disease 2 had any Lowe syndrome-like phenotype,
subclinical cataract, hypotonia, severe intellectual
disability, or dysmorphic features, but all had short stature
(Table IV).32
A Diagnosis of Dent Disease Was Established in 19
of 23 Patients by Genetic Testing, and 10 Novel
Mutations Were Identified
In the CLCN5 gene, we identified 14 mutations in 15 patients
from 14 families, including 8 novel mutations (Table I). The
2 nonsense mutations and 3 frame shift mutations, c.242G>A
(p.Trp81*), c.813C>G (Tyr271*), c.746_749del (p.Ala249-
Valfs*4), c.1620dup (Ala541Cysfs*19), and c.1743_1765dup
(p.Arg590Glnfs*4), introduce premature stop codon(s) and
lead to a predicted truncation of 666, 476, 495, 188,
and 154 amino acids at the C terminus of the encoding
protein, respectively. The c.242G>A (p.Trp81*), c.813C>G
(Tyr271*), and c.746_749del (p.Ala249Valfs*4) mutations
wipe out part of the transmembrane regions and the 2
cystathionine betasynthase (CBS) domains. The c.1620dup
(Ala541Cysfs*19) mutation truncate the 2 CBS domains and
c.1743_1765dup (p.Arg590Glnfs*4) truncate the part of the
first and all the second CBS domain. mRNAs transcribed
from the truncated genes are expected to be degraded by
nonsense-medicated decay.33 Tests of the boys’ mothers
showed that c.746_749del, c.813C>G, and c.242G>A were
inherited from the probands’ mothers. The origin of the
other 2 mutations c.1620dup and c.1743_1765dup, however,ent disease
Mutation Mutation type Novel/known
37G>A (p.Gly513Arg) Missense Known
3T>C (p.Leu278Ser) Missense Novel
6_749del (p.Ala249Valfs*4) Deletion Novel
9A>T (p.Leu263Phe) Missense Novel
3 A>C (p.Ser265Arg) Missense Novel
10C>T (p.Arg704*) Nonsense Known
C>T (p.Arg28*) Nonsense Known
3C>G (p.Tyr271*) Nonsense Novel
3C>G (p.Tyr271*) Nonsense Novel
2G>A (p.Trp81*) Nonsense Novel
20dup (p.Ala541Cysfs*19) Duplication Novel
0_721del (p.Glu241Glyfs*26) Deletion Known
: 49,780,222 - 49,840,741 del Deletion Known
7del (p.Ser40Alafs*8) Deletion Known
43_1765dup (p.Arg590Glnfs*4) Duplication Novel
3_838del (p.Glu278_Leu279del) Deletion Novel
3_838del (p.Glu278_Leu279del) Deletion Novel
3del (p.Arg175Glyfs*10) Deletion Novel
3del (p.Arg175Glyfs*10) Deletion Novel
ents are each from independent families.
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Table II. Urinary tests of patients with Dent disease
24-hour urine
protein, g/d*
Albumin,
mg/L†
a1-microglobulin,
mg/Lz b2MG, mg/L
x
Low-molecular-weight
proteins/total protein, %
24hUCa,
mg/kg/24h{
Ca/Cr,
mg/mg**
Dent disease 1, mean  SD 1.3  0.9 231.9  175.2 239.4  163.9 121.1  93.9 59.6  7.8 6.9  1.5 0.39  0.19
Dent disease 2, mean  SD 1.3  0.5 396.5  72.9 364.7  144.4 287.3  232.3 55.2  9.8 6.5  2.2 0.41  0.14
Hematuria was found in P1, P2, P7, P10, P13, P15, P16, P17, P18, and P19. Glucosuria was found in P3, P4, P7, and P11. Aminoaciduria was found in P3, P4, P5, P7, P8, and P9.
*Normal value: 0-0.1 g/day.
†Normal value: 0-30 mg/L.
zNormal value: 0-12 mg/L.
xNormal value: 0-0.206 mg/L.
{Normal value <4 mg/kg/24h.
**Normal value <0.2 mg/mg.
July 2016 ORIGINAL ARTICLESwas uncertain as the probands’ mothers were unavailable for
analysis. We also identified 3 missense mutations, c.789A>T
(p.Leu263phe), c.793A>C (p.Ser265Arg), and c.833T>C
(p.Leu278Ser), in conserved amino acids that are predicted
to be damaging or probably damaging by SIFT and
PolyPhen2. The c.789A>T (p.Leu263phe) and the c.793A>C
(p.Ser265Arg) occurred in the fifth transmembrane region;
the c.833T>C (p.Leu278Ser) occurred in the sixth transmem-
brane region and is predicted to replace a hydrophobic
leucine with hydrophilic serine.
We identified 2 novel mutations in the OCRL1 gene,
c.833_838del (Glu278_Leu279del) and c.523del (Arg175-
Glyfs*10) in 4 patients from 2 families (Table I). TheTable III. Blood biochemistry tests of patients with Dent dis
Hyponatremia Hypokalemia Hypochloremia Hypoca
Dent disease 1
P1    
P2    
P3    
P4 + + + 
P5 + + + +
P6 + + + +
P7  +  
P8  +  +
P9  +  
P10    
P11    
P12    
P13    
P14    
P15    
Abnormality 3/15 6/15 3/15 3/
Dent disease 2
P16    
P17    
P18  + + 
P19    
Abnormality 0/4 1/4 1/4 0
Blood urine
nitrogen, mmol/L*
Serum creatinine,
mg/dL†
Estimat
filtra
mL/m
Dent disease 1, mean  SD 6.2  6.4 1.0  2.2 110
Dent disease 2, mean  SD 5.9  2.4 1.0  0.8 82
ND, not detected.
P8 and P9 from family 8; P16 and P17 from family 15; P18 and P19 from family 16; the other patie
*Normal value: 1.8-6.4 mmol/L (<1 month), 2.5-6.4 mmol/L (1 month to <12 years), 2.9-7.5 mmo
†Normal value: 0.45-0.81 mg/dL (<7 days), 0.29-0.40 mg/dL (7 days to <1 month), 0.25-0.38 mg/dL
0.66-0.96 mg/dL (>18 years).31
zNormal value >90 mL/min/1.73m2.
xNormal value: 13-25 ng/mL.
{Normal value: 1-200 U/L.
**Normal value: 15-68.3 pmol/L.
Dent Disease in Chinese Children and Findings from Heterozygo
and 10 Novel Mutationsc.833_838del (Glu278_Leu279del), an in-frame deletion,
is predicted to delete the glutamic acid and leucine
at positions 278 and 279, respectively. These 2 amino
acids are conserved between human and the 5 orthologs
analyzed and are located in the endonuclease/exonuclease/
phosphatase family domain, the patient’s mother carried
the mutation. c.523del (Arg175Glyfs*10) is a frameshift
mutation introducing a premature stop codon and
removing 718 amino acids from the C terminus of the
wild-type protein, which harbors the endonuclease/
exonuclease/phosphatase family domain and the GTPase-
activator protein towards Rho/Rac/Cdc42-like small
GTPases domains; the patients’ mother also carried theease
lcemia Hypophosphatemia Hypomagnesemia Acidosis/alkalosis
  /
 + /
  /
+ + /+
+ + /+
+ + /+
+  /
 + +/
+  /
  /
 ND /
  /
  /
  /
  /
15 5/15 5/14 1/15j3/15
  /
  /
  /+
  /
/4 0/4 0/4 0/4j1/4
ed glomerular
tion rate,
in/1.73 m2z
25-OH-vitamin
D3, ng/mL
x
Alkaline
phosphatase, U/L{
Intact parathyroid
hormone, pmol/L**
.7  48.6 18.5  8.4 316.6  145.7 81.7  113.6
.6  49.1 29.5  11.3 398.5  166.7 62.5  71.4
nts are each from independent families.
l/L (12-18 years), 2.9-8.6 mmol/L (>18 years).30
(1 month to <6 years), 0.43-0.61 mg/dL (6 years to <14 years), 0.62-0.71 mg/dL (14-18 years),
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Table IV. Growth data and clinical features of patients with Dent disease
Gestational age
(week + day) Age, y
Age at
presentation, y
Ages at
diagnosis, y
Birth
weight, kg
(percentile)*
At diagnosis
Nephrocalcinosis/
nephrolithiasisz Rickets
Height, cm
(varied)†
Weight, kg
(varied)†
Dent disease 1
P1 40 7.8 2.3 4.3 4.1 (>P97) 112.3 (+1.4 SD) 19 (+0.9 SD) No/No Classical
P2 37 + 3 7.8 2.6 3.7 3.7 (>P97) 102 (+0.0 SD) 19 (1.4 SD) No/No Mild
P3 40 + 3 3.4 1.1 1.3 3.6 (P76) 75 (2.0 SD) 9.0 (1.8 SD) No/No Mild
P4 38 10.9 3.8 8.5 3.9 (>P97) 110 (3.8 SD) 21.5 (1.5 SD) No/No Mild
P5 42 + 3 15.3 1.2 13.2 4.25 (>P97) 126 (4.7 SD) 24.5 (3.5 SD) No/No Mild
P6 38 14.8 3.7 10.7 3.5 (P92) 101 (6.5 SD) 18.5 (3.5 SD) No/No Mild
P7 41 7.9 4.5 4.8 3.8 (P88) 105 (1.1 SD) 19 (+0.15 SD) Yes/No Mild
P8 ND 30.6 12 28 ND 150 (3.8 SD) 36 (3.9 SD) No/No No
P9 37 + 3 14.6 9 12.5 3.3 (P87) 146 (1.2 SD) 35 (0.9 SD) No/No No
P10 39 + 3 4.5 1.8 2.1 3.5 (P77) 87 (1.0 SD) 12 (0.55 SD) No/No Mild
P11 39 + 3 6.6 3.3 4.2 4.3 (>P97) 106 (+0.1 SD) 17 (+0.0 SD) No/No No
P12 39 + 6 11.8 3 8 4.4 (>P97) 125 (0.9 SD) 22.5 (1.2 SD) No/No No
P13 41 14.8 1 12 3.4 (P53) 125.6 (2.65 SD) 44 (+0.1 SD) No/No No
P14 38 12.8 4.5 11 2.4 (P4) 134 (1.1 SD) 25 (1.8 SD) No/No No
P15 41 9.9 4.6 5.1 3.9 (P94) 111 (0.1 SD) 19 (+0.0 SD) No/No No
Mean  SD 11.5  6.5 3.9  3.0 8.6  6.6
Abnormality 9/14 5/15 3/15 1/15 8/15
Dent disease 2
P16 39 + 5 8.1 4.4 4.9 2.7 (P6) 96.6 (3.5 SD) 14.5 (2.2 SD) No/No No
P17 40 + 3 5.6 2.5 3.3 3.0 (P22) 87.5 (2.2 SD) 10.5 (3.2 SD) No/No No
P18 40 30.5 1 30 3.6 (P80) 156 (2.7 SD) 56 (0.7 SD) No/No No
P19 39 + 1 17.7 0.7 15 3.4 (P71) 146 (3.7 SD) 50 (0.8 SD) No/No No
Mean  SD 15.4  11.2 2.2  1.7 13.3  12.2
Abnormality 1/4 4/4 2/4 0/4 0/4
ND, records not available.
P8 and P9 from family 8; P16 and P17 from family 15; P18 and P19 from family 16; the other patients are each from an independent families.
*Normal range: (P10-P90).32
†Varied when compared with mean.
zNephrocalcinosis and nephrolithiasis were absent in all patients at diagnosis, P7 was found to have nephrocalcinosis at follow-up at the age of 6 years and 9 months.
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identified in the OCRL1 gene were located at the 50 portion
of the gene.
Growth Abnormality in the 2 Types of Patients/
Fetuses with Dent Disease
Retrospective study of the maternal records of the mothers of
patients showed that 8 of 14 patients with Dent disease 1 were
LGA, and one was small for gestational age (SGA) who had
intrauterine growth restriction by ultrasound compared
with Chinese reference standards (Table IV).34 One patient
with Dent disease 2 was SGA (Table IV). There were no
evident maternal conditions that are known to cause fetal
enlargement or growth restriction, such as diabetes or
placental problems. The pregnancies were uneventful.
These patients were born by vaginal delivery with no
medical complications. At the time of diagnosis, reduced
weight for age was found in 3 of 15 patients with Dent
disease 1 and 2 of 4 patients with Dent disease 2, and 5 of
15 patients with Dent disease 1 and 4 of 4 patients with
Dent disease 2 had height below the second SD (Table IV).
No birth defects were evident pre- or postneonatally.
Nephrocalcinosis and Nephrolithiasis Were Not
Observed at Diagnosis in All Patients but Were
Common in Heterozygous Mothers
Nephrocalcinosis and nephrolithiasis were not present in any
of the 19 confirmed patients at diagnosis, although 1 (P7) was208found to have nephrocalcinosis at follow-up at the age of
6 years and 9 months (Table IV). In contrast,
nephrolithiasis or nephrocalcinosis was present in 6 of 14
(42.8%) of the mothers (mothers of P5, P11, P12, P14,
P15, and P16 from 6 families). The age at which
nephrolithiasis or nephrocalcinosis was identified was 21 to
40 years. Urinary Ca/Cr and 24hUCa were normal in
mothers, except the mother of 2 siblings (P18, P19, family
16), whose 24hUCa was 7.2 mg/kg/24h and Ca/Cr ratio
was 0.343 mg/mg. Routine urine testing also was normal in
all except 2 tested mothers (P3, P5 from family 3 and 5,
respectively) who were pregnant at the time of our
investigation and had occasional mild proteinuria and
increased urinary a1-microglobulin and b2MG. Urinary
b2MG was increased slightly in 11 of 13 of carrier mothers,
including the 2 pregnant mothers. Estimated glomerular
filtration rate was normal in all mothers whose data were
available.
Greater Rate of Rickets in Patients with Dent
Disease 1
At diagnosis, we observed rickets in 8 of 15 (53.3%) patients
with Dent disease 1 (Table IV). Among them 7 showed mild
skeletal changes, mild pigeon chest (P4, P5, P6), pectus
excavatum (P5, P10), rachitic rosary (P3, P5, P6), Harrison
groove (P2, P4, P5, P6, P10), O-shaped (P4, P5, P7) or X-
shaped lower limbs with genu varus (P6), caput quadratum
(P3, P4), decreased bone density and/or delayed bone ageLi et al
July 2016 ORIGINAL ARTICLES(P2-P7, P10), and 1 (P1) exhibited a “pigeon chest” and
extensive hypodensity in the ulna, radius, carpal bones,
metacarpal bones, and phalanges of left wrist.
Structural Modeling and Bioinformatics Analyses of
the Mutant Proteins
Structural modeling and bioinformatics analyses were per-
formed to study the missense mutations c.789A>T
(p.Leu263Phe), c.793A>C (p.Ser265Arg), and c.833T>C
(p.Leu278Ser) in CLCN5 and the impact of the in-frame
deletion mutation c.833_838del (p.Glu278_Leu279) found
in OCRL1.
Consistent with previous human chloride channel studies
based on crystal structures of prokaryotic homologues,35,36
our homology model predicted that the mutation of Leu263-
Phe, Ser265Arg, and Leu278Ser are located in the 2 helices
(Figure, A and B; available at www.jpeds.com), which are
proposed to be involved in the formation of the dimer
interface. Both sequence and structure alignments show
that the Leu263 site is conserved in chloride channels and
was located at the dimer interface (Figure, C and D). The
closest distance between the side chains of the Leu residues
from the 2 monomers is 3.7 A in the chloride channel
transporter from Cyanidioschyzon merolae and 3 A in
chloride channel transporter from Escherichia coli.
Therefore, substitution with a larger phenylalanine residue
at Leu263 site may disrupt the assembly of the dimer. In
the mutation p.Ser265Arg, the small wild-type hydrophilic
Ser265 residue was oriented towards a hydrophobic pocket,
so a large hydrophilic arginine substitution at this location
might disrupt protein folding. In the mutation
p.Leu278Ser, it has been reported that replacing Leu278
with phenylalanine was associated with a marked chloride
current reduction in a functional assessment in Xenopus
oocytes.37 This site is in a hydrophobic environment
(Figure, A and B). Changing leucine to a hydrophilic serine
could have impact on the activity or stability of the dimeric
form of the protein. OCRL1 belongs to the type II inositol
polyphosphate-5-phosphatases, which react with substrate
in an Mg2+-dependent manner.38 It has been suggested that
residue Glu278 in OCRL1 is responsible for Mg2+ binding
(Figure, E) and is involved in the interaction with
phosphatidylinositol, hence critical for the enzymatic
activity of OCRL1. Structure alignment shows that Glu278
was orientated towards the catalytic pocket with a highly
conserved conformation (Figure, E). The Leu279 residue,
altered in the same mutation, is not as conserved as
Glu278, but is involved in hydrophobic interactions within
the normal structure of OCRL1 (Figure, E). Thus deletion
of Glu278 and Leu279 may abolish the enzymatic activity
or stability of the protein.Discussion
We performed detailed clinical and genetic investigations in
19 confirmed patients from 16 families. Onset of disease wasDent Disease in Chinese Children and Findings from Heterozygo
and 10 Novel Mutationsinsidious in all patients, and misdiagnosis occurred in 16 pa-
tients; 11 patients were treated unnecessarily before the cor-
rect diagnosis was reached, which illustrates the difficulties in
reaching the correct diagnosis in early childhood, where the
clinical manifestations are not typical of those described in
adults. In particular, nephrocalcinosis or nephrolithiasis,
which are classic features in adults, were not present before
the correct diagnosis was reached, although nearly all of the
patients had elevated 24hUCa. In contrast to this low fre-
quency, there was a high rate of nephrolithiasis and nephro-
calcinosis in the mothers. The low frequency of
nephrocalcinosis or nephrolithiasis in our patients may
well be because these conditions need time to develop. This
result underlines that nephrocalcinosis or nephrolithiasis
should not be required for the diagnosis of Dent disease in
children.
It has been reported that rickets or osteomalacia occur in a
minority patients2; however, we identified it in 8 of 15
(53.3%) cases of rickets in Dent disease 1, which is much
greater than the reported frequency in Japanese patients.13
A similar rickets rate also was reported in Italian patients
with Dent disease.39 It is known that rickets and osteomalacia
in Dent disease can be corrected by vitamin D supplementa-
tion. The greater rate of rickets in our cases may have been
exacerbated by the generally lower calcium intake, including
lower milk consumption by Chinese children.
In reviewing the maternal records and the history of our
patients, we found that 8 of 14 patients with Dent disease 1
were LGA. Overall, 1 patient with Dent disease 1 was SGA
with intrauterine growth restriction, and 1 patient with
Dent disease 2 was SGA. Reviewing the literature, we only
found 1 relevant paper that reported 2 patients with Dent dis-
ease 1 who were LGA, who subsequently had growth restric-
tion after birth.16 Intrauterine growth of these patients seems
to be a neglected area, probably because of the fact that the
disease is only recognized later in life. Our study, combined
with the previous report, implies that Dent disease 1 may in-
crease intrauterine growth, but this implication requires in-
dependent validation. It is known that CLCN5 is expressed
in the placenta,40 providing a potential link between fetal
growth and Dent disease 1.
Our investigation shows the rate of genetic testing in estab-
lishing a definitive diagnosis of Dent disease 1 and 2, partic-
ularly in early childhood, and underlines that this would
avoid inappropriate treatment. We observed a high rate of
rickets in our patients. We also identified a high rate of neph-
rocalcinosis or nephrolithiasis in carrier mothers but none in
the patients at diagnosis. Finally, the possibility exists that
Dent disease could be associated with aberrant intrauterine
growth. Environmental effects on Dent disease phenotypes,
including rickets, merit further investigation. n
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Figure. A andB,Ribbon and surface representation of the model of the human CLC-5monomer. Themutant sites are marked and
colored in green. C, Sequence alignment between human CLC-5 and its homologues: CmCLC (chloride channel transporter from
Cyanidioschyzonmerolae) andEcCLC (chloridechannel transporter fromEscherichia coli).D,Structure alignment of thepart identical
toCbetweenCmCLC (yellow, PDB ID: 3ORG)andEcCLC (lime, PDB ID: 1KPK)dimer from the sameviewofA.E,Structure alignment
betweenOCRL1 (cyan, PDB ID: 4CMN) andhomologousproteins: Type II inositol 1,4,5-trisphosphate 5-phosphatase (INPP5b, slate,
PDB ID: 4CML) in complexwith phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2), SH2domain-containing inositol 5
0-phosphatase 2
(SHIP2,gray, PDB ID: 3NR8). Themutant residuesGlu278, Leu279, and the correspondingwild-type residues in the homologuesand
the phosphate group fromOCRL1 structure are presented as sticks. Catalytic residues His524, Asp422, and residues involved in the
hydrophobic interactions with Leu279 in OCRL1 and the PI(3,4)P2 substrate from INPP5b structure are all presented as thin lines.
Mg2+ in the OCRL1 structure is shown as a cyan sphere.
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